A Two Part Seamless, Multi-Center Randomized, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy Patients
Latest Information Update: 29 Apr 2024
At a glance
- Drugs Risdiplam (Primary) ; Risdiplam (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms SUNFISH
- Sponsors Chugai Pharmaceutical; Roche
- 23 Oct 2023 Status changed from active, no longer recruiting to completed.
- 08 Sep 2023 Planned End Date changed from 2 Sep 2023 to 29 Sep 2023.
- 19 Jun 2023 This trial has been completed in Germany, according to European Clinical Trials Database record.